阿片受体激动-拮抗剂的镇痛作用及不良反应研究进展

陈泽权; 肖国伟; 敖健; 蒋为薇

doi:10.6039/j.issn.1001-0408.2023.18.23

您当前的位置：

首页 >

文章列表页 >

阿片受体激动-拮抗剂的镇痛作用及不良反应研究进展

综述 | 更新时间：2023-09-22

- 阿片受体激动-拮抗剂的镇痛作用及不良反应研究进展
- Research progress on analgesic effect and adverse drug reactions of opioid receptor agonist-antagonists
- 中国药房 2023年34卷第18期页码：2299-2304
- 作者机构：
  
  1.巫山县中医院骨伤科，重庆　404700
  2.重庆医科大学附属第二医院药学部，重庆　400010
- 作者简介：
  
  研究方向：骨科学。E-mail：514154283@qq.com
  副主任药师，副教授，博士。研究方向：临床药学疼痛方向。E-mail：304035@cqmu.edu.cn
- 基金信息：
  
  白求恩公益基金会“2022白求恩·求索-药学科研能力建设”项目(X2023-206)
- DOI：10.6039/j.issn.1001-0408.2023.18.23
  中图分类号： R971+.1
- 纸质出版日期：2023-09-30，
  
  收稿日期：2023-05-31，
  
  修回日期：2023-08-16，
扫描看全文
陈泽权,肖国伟,敖健等.阿片受体激动-拮抗剂的镇痛作用及不良反应研究进展 ^Δ[J].中国药房,2023,34(18):2299-2304.

CHEN Zequan,XIAO Guowei,AO Jian,et al.Research progress on analgesic effect and adverse drug reactions of opioid receptor agonist-antagonists[J].ZHONGGUO YAOFANG,2023,34(18):2299-2304.
陈泽权,肖国伟,敖健等.阿片受体激动-拮抗剂的镇痛作用及不良反应研究进展 ^Δ[J].中国药房,2023,34(18):2299-2304. DOI： 10.6039/j.issn.1001-0408.2023.18.23.

CHEN Zequan,XIAO Guowei,AO Jian,et al.Research progress on analgesic effect and adverse drug reactions of opioid receptor agonist-antagonists[J].ZHONGGUO YAOFANG,2023,34(18):2299-2304. DOI： 10.6039/j.issn.1001-0408.2023.18.23.

摘要

阿片受体激动-拮抗剂是一类对阿片受体兼有激动和拮抗作用的药物。已经上市的这类药物主要包括喷他佐辛、布托啡诺、纳布啡、丁丙诺啡和地佐辛等。与吗啡、芬太尼等单纯阿片受体激动剂相比，该类药物具有镇痛效果较强，成瘾性较弱，咳嗽、瘙痒以及呼吸抑制等副作用少的优点。由于阿片受体激动-拮抗剂在不同内源性阿片受体（μ、κ、δ等）间具有不同的倾向性作用，基于不同受体亚型，可在情绪影响、药物依赖方面表现出不同甚至相反的作用，因此合理地使用这类药物可以有效地减少阿片类药物导致的不良反应以及药物滥用的发生。随着学界对内源性阿片各受体亚型及相关药物研究的深入，阿片受体激动-拮抗剂在改善阿片类药物不良反应和提高患者药物依从性方面有着广泛的应用空间和前景。

Abstract

Opioid receptor agonist-antagonists are a class of drugs which have both agonistic and antagonistic effects on opioid receptors. These drugs already on the market mainly include pentazocine， butorphanol， nalbuphine， buprenorphine， dezocine and so on. Compared with pure opioid receptor agonists such as morphine and fentanyl， these drugs have strong analgesic effects， less addictive， and less side effects such as cough， itching and respiratory depression. Due to the different tendentious effects of opioid receptor agonists-antagonists among different endogenous opioid receptors （μ， κ， δ， etc.）， different receptors of subtypes can exhibit different or even opposite effects in terms of affecting emotions and drug dependence. Therefore， the rational use of these drugs can effectively reduce the occurrence of adverse reactions and drug abuse caused by opioid drugs. With the deepening of research on various endogenous opioid receptor subtypes and related drugs in the academic community， opioid receptor agonists-antagonists have broad application space and prospects in improving adverse reactions to opioid drugs and enhancing patient drug compliance.

关键词

阿片受体激动-拮抗剂内源性阿片受体镇痛不良反应

Keywords

endogenous opioid receptorsanalgesiaadverse drug reactions

references

LAMBERT D G. The nociceptin/orphanin FQ receptor：a target with broad therapeutic potential[J]. Nat Rev Drug Discov，2008，7（8）：694-710.

THOMPSON G L，LANE J R，COUDRAT T，et al. Biased agonism of endogenous opioid peptides at the μ-opioid receptor[J]. Mol Pharmacol，2015，88（2）：335-346.

VALENTINO R J，VOLKOW N D. Untangling the complexity of opioid receptor function[J]. Neuropsychopharmacology，2018，43（13）：2514-2520.

JASCHKE N，PÄHLIG S，PAN Y X，et al. From pharmacology to physiology：endocrine functions of μ-opioid receptor networks[J]. Trends Endocrinol Metab，2021，32（5）：306-319.

CHIAPPINI S，VICKERS-SMITH R，GUIRGUIS A，et al. Pharmacovigilance signals of the opioid epidemic over 10 years：data mining methods in the analysis of pharmacovigilance datasets collecting adverse drug reactions（ADRs）reported to EudraVigilance（EV）and the FDA adverse event reporting system（FAERS）[J]. Pharmaceuticals（Basel），2022，15（6）：675.

STEIN C. Opioid receptors[J]. Annu Rev Med，2016，67：433-451.

NEGUS S S，BEAR A E，FOLK J E，et al. Role of delta opioid efficacy as a determinant of mu/delta opioid interactions in rhesus monkeys[J]. Eur J Pharmacol，2009，602（1）：92-100.

BRUCHAS M R，LAND B B，CHAVKIN C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors[J]. Brain Res，2010，1314：44-55.

FAOUZI A，VARGA B R，MAJUMDAR S. Biased opioid ligands[J]. Molecules，2020，25（18）：4257.

PAWAR A，RAJALAKSHMI A K，UPADHYAY R P. Pentazocine use among people who inject drugs in India[J]. Asian J Psychiatr，2015，16：3-6.

MAHAPATRA S J，JAIN S，BOPANNA S，et al. Pentazocine，a kappa-opioid agonist，is better than diclofenac for analgesia in acute pancreatitis：a randomized controlled trial[J]. Am J Gastroenterol，2019，114（5）：813-821.

SAHU K K，SAWATKAR G U，SAHU S A，et al. Pentazocine-induced skin ulcers[J]. Am J Med Sci，2020，359（3）：182-183.

JI J F，LIN W Z，VRUDHULA A，et al. Molecular interaction between butorphanol and κ-opioid receptor[J]. Anesth Analg，2020，131（3）：935-942.

ZHANG C Y，JIANG S L，LU Y，et al. Butorphanol tartrate mitigates cellular senescence against tumor necrosis factor-α（TNF-α）in human HC-a chondrocytes[J]. Bioengineered，2022，13（3）：5434-5442.

HUANG Y S，LI S H，CHEN H X，et al. Butorphanol reduces the neuronal inflammatory response and apoptosis via inhibition of p38/JNK/ATF2/p53 signaling[J]. Exp Ther Med，2022，23（3）：229.

ZHANG J，MIAO S，TU Q，et al. Effect of butorphanol on opioid-induced cough：a meta-analysis of randomized controlled trials[J]. Drug Des Devel Ther，2018，12：3263-3268.

ZHU Z，ZHANG W. Efficacy and safety of butorphanol use in patient-controlled analgesia：a meta-analysis[J]. Evid Based Complement Alternat Med，2021，2021：5530441.

LABIB A，JU T，LIPMAN Z M，et al. Evaluating the effectiveness of intranasal butorphanol in reducing chronic itch[J]. Acta Derm Venereol，2022，102：adv00729.

SHAH B，GUPTA R，SARKAR S，et al. Injection butorphanol dependence：a case report[J]. Asian J Psychiatr，2018，35：45-46.

DELANDER G E，PORTOGHESE P S，TAKEMORI A E. Role of spinal mu opioid receptors in the development of morphine tolerance and dependence[J]. J Pharmacol Exp Ther，1984，231（1）：91-96.

INAN S，TORRES-HUERTA A，JENSEN L E，et al. Nalbuphine，a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus，decreases IL-31，and increases IL-10 in mice with contact dermatitis[J]. Eur J Pharmacol，2019，864：172702.

RUAN D J，WANG Y Y，LI S S，et al. Nalbuphine alleviates inflammation by down-regulating NF-κB in an acute inflammatory visceral pain rat model[J]. BMC Pharmacol Toxicol，2022，23（1）：34.

LEE S C，WANG J J，HO S T，et al. Nalbuphine coad-ministered with morphine prevents tolerance and dependence[J]. Anesth Analg，1997，84（4）：810-815.

IBRAHIM A M，OBAIDI Z，RUAN G，et al. Nalbuphine for opioid-induced urine retention[J]. Ann Intern Med，2023，169（12）：894-895.

INFANTINO R，MATTIA C，LOCARINI P，et al. Buprenorphine：far beyond the “ceiling”[J]. Biomolecules，2021，11（6）：816.

COE M A，LOFWALL M R，WALSH S L. Buprenorphine pharmacology review：update on transmucosal and long-acting formulations[J]. J Addict Med，2019，13（2）：93-103.

SHULMAN M，WAI J M，NUNES E V. Buprenorphine treatment for opioid use disorder：an overview[J]. CNS Drugs，2019，33（6）：567-580.

MADISON C A，EITAN S. Buprenorphine：prospective novel therapy for depression and PTSD[J]. Psychol Med，2020，50（6）：881-893.

ZHU F，DUAN W，ZHONG C，et al. The protective effects of dezocine on interleukin-1β-induced inflammation， oxidative stress and apoptosis of human nucleus pulposus cells and the possible mechanisms[J]. Bioengineered，2022，13（1）：1399-1410.

WU F X，BABAZADA H，GAO H，et al. Dezocine alleviates morphine-induced dependence in rats[J]. Anesth Analg，2019，128（6）：1328-1335.

YU F，ZHOU J，XIA S Y，et al. Dezocine prevents posto-perative hyperalgesia in patients undergoing open abdominal surgery[J]. Evid Based Complement Alternat Med，2015，2015：946194.

AHSAN M Z，ZHAO M J，SHOAIB R M，et al. Comparative study of dezocine，pentazocine and tapentadol on antinociception and physical dependence[J]. Life Sci，2021，285：119996.

ZHAO P，WU Z X，LI C R，et al. Postoperative analgesia using dezocine alleviates depressive symptoms after colorectal cancer surgery：a randomized，controlled，double-blind trial[J]. PLoS One，2020，15（5）：e0233412.

DONG Y X，CHANG X H. Comparison of five prophylactically intravenous drugs in preventing opioid-induced cough：a Bayesian network meta-analysis of randomized controlled trials[J]. Front Pharmacol，2021，12：684276.

WANG X J，CHEN Y，WANG Z F，et al. Effect of dezocine on hemodynamic indexes of postoperative patients with traumatic brain injury（TBI）：a pilot study[J]. Front Pharmacol，2022，13：665107.

FERRACANE M J，BRICE-TUTT A C，COLEMAN J S，et al. Design，synthesis，and characterization of the macrocyclic tetrapeptide cyclo[pro-sar-phe-d-phe]：a mixed opioid receptor agonist-antagonist following oral admini-stration[J]. ACS Chem Neurosci，2020，11（9）：1324-1336.

KIM E S. Oxycodone/naloxone prolonged release：a review in severe chronic pain[J]. Clin Drug Investig，2017，37（12）：1191-1201.

DUPOIRON D，STACHOWIAK A，LOEWENSTEIN O，et al. A phase Ⅲ randomized controlled study on the efficacy and improved bowel function of prolonged-release（PR）oxycodone-naloxone（up to 160/80 mg daily）vs oxycodone PR[J]. Eur J Pain，2017，21（9）：1528-1537.

CHEN X T，PITIS P，LIU G D，et al. Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand，[（3-methoxythiophen-2-yl）methyl]（{2-[（9R）-9-（pyridin-2-yl）-6-oxaspiro-[4.5]decan-9-yl]ethyl}）amine（TRV130），for the treatment of acute severe pain[J]. J Med Chem，2013，56（20）：8019-8031.

DEUIS J R，DVORAKOVA L S，VETTER I. Methods used to evaluate pain behaviors in rodents[J]. Front Mol Neurosci，2017，10：284.

AKGÜN E，LUNZER M M，TIAN D F，et al. FBNTI，a DOR-selective antagonist that allosterically activates MOR within a MOR-DOR heteromer[J]. Biochemistry，2021，60（18）：1413-1419.

OLSON K M，HILLHOUSE T M，BURGESS G E，et al. Delta opioid receptor-mediated antidepressant-like effects of diprenorphine in mice[J]. J Pharmacol Exp Ther，2023，384（3）：343-352.

IMAM M Z，KUO A，GHASSABIAN S，et al. Intracerebroventricular administration of CYX-6，a potent μ-opioid receptor agonist，a δ- and κ-opioid receptor antagonist and a biased ligand at μ，δ & κ-opioid receptors，evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine[J]. Eur J Pharmacol，2020，871：172918.

SUN J F，WANG Y H，CHAI J R，et al. Pharmacological characterization and therapeutic potential for the treatment of opioid abuse with ATPM-ET，an N-ethyl substituted aminothiazolomorphinan with κ agonist and μ agonist/antagonist activity[J]. Eur J Pharmacol，2014，740：455-463.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

抗肿瘤分子靶向药物致化疗相关性腹泻的研究进展

奥马珠单抗治疗儿童过敏性疾病的安全性分析

不同肠内营养制剂用于重症急性胰腺炎的疗效及胃肠道耐受性研究

替加环素致严重肾功能不全患者凝血功能异常的回顾性分析

重庆市2015－2022年药物过敏性休克救治使用肾上腺素情况的回顾性研究